March 30, 2012
-- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will present two lectures entitled "Optimizing Lead Compound Selection Using Mechanistic Physiological Modeling" and "Qualifying Mechanistic Physiological Models for Use in Pharmaceutical Discovery and Development"
on April 2, 2012, as part of the European Foundation of Medicinal Chemists conference “Target Selection through Application of Chemical and Systems Biology” in Oegstgeest, The Netherlands. Dr. Christina Friedrich will present the two lectures which highlights the use of systems pharmacology models in lead compound selection and Rosa’s Model Qualification Method (MQM). The course participants will learn how mechanistic systems pharmacology modeling can be used to optimize lead compound selection and methods for qualifying these models to improve scientific insights and enhance the quality of decision-making throughout the pharmaceutical discovery/development pipeline.
"This event is the first European event in the series of MQM-focused educational activities in 2012. We are pleased to bring the MQM to an EU audience, and demonstrate its excellence as a quality standard for systems pharmacology modeling." said Dr. Rebecca Baillie, Rosa's Chief Scientist. "We are looking forward to the many other events to show the power and impact of mechanistic, physiological modeling in drug development.”
Rosa informs our customer's most critical decisions - from preclinical through clinical development - with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/
pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these approaches, Rosa's clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa's staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/
antivirals. For more information, visit www.rosaandco.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
# # #
Rosa creates robust mathematical models that simulate drug effects and trial outcomes. Modeling and Simulation complement traditional experimental methods, enabling unique insights that streamline drug development and regulatory interactions.